SynderBio Inc. — Department of Health and Human Services SBIR Phase I: 172

Description

Summary Single cell sequencing SCS is a disruptive new technology that offers an unprecedented ability to interrogate the genomics DNA RNA of single cells to understand the complex biologies of normal and diseased tissues SCS is not only important for basic research but also represents a next generation of diagnostic approaches particularly for cancer While multiple SCS platforms have been marketed or are under development all of these rely on high quality preparations of single viable cells in a fluid suspension to enter their respective workflows This is not a trivial undertaking as enzymatically digested normal or diseased tissues contain dead or dying cells and cell aggregates that may confound SCS Current cell preparation methods for SCS such as fluorescence activated cell sorting FACS or dead cell removal kits are suboptimal in that they often require a significant investment of time money and or training require multiple protocols and or result in a poor yield of viable cells which is particularly problematic for scarce clinical specimens The SynderBio Randamp D team has developed a proprietary approach for separating cell types based on their differential responses to brief pulses of fluid shear stress FSS Our preliminary data supports our hypothesis that we can use this technology to rapidly andlt min eliminate dead dying cells and dissociate cell aggregates from cell suspensions Our Specific Aims and Milestones for this Phase I SBIR feasibility project are as follows Specific Aim Calibrate the performance characteristics of SynderBioandapos s FSS technology for SCS Milestone Achieve viable single cell preparation with yield Specific Aim Compare SynderBioandapos s FSS technology to existing cell preparation methods Milestones Achieve significantly better performance characteristics andlt min viable single cells yield with purity comparable to that of FACS or dead cell removal kits from competitors Phase II Aims will then be to transform SynderBioandapos s current pre prototype device into a commercial ready product distribute a limited number of these devices to thought leaders and potential strategic partners in the field and expand the side by side comparison with competing technologies to other relevant applications in the field Phase II work will be focused on successful prototyping and in depth testing designed to obtain the data required by potential Phase III industry collaborators investors to engage in the next steps required for Phase III commercialization The commercial opportunity for SynderBioandapos s product is significant The global cell isolation separation market alone is expected to reach $ B in at a CAGR of SynderBioandapos s technology is also applicable to cell preparation for other purposes such as FACS Thus we expect the successful development of SynderBioandapos s technology to have a major positive impact on human health and to address significant commercial opportunities related to the use of SCS for understanding and differentiating normal and diseased tissue biology PROJECT NARRATIVE The proposed research is relevant to public health because we seek to improve the methods for preparing cell suspensions for single cell sequencing which is an emerging technology that will allow us to better understand the biology of normal and diseased tissues and to more effectively diagnose diseases such as neurological disorders and cancer Current methods for cell preparation are unsatisfactory because they require a significant investment of time money and or training require multiple protocols and or result in a poor yield of viable cells which is particularly problematic for scarce clinical specimens SynderBio proposes to develop a novel proprietary method for preparing single viable cell suspensions faster cheaper and of higher quality than is currently possible and to thereby expand the utility of single cell sequencing greatly improving human health while addressing a multi billion dollar market